Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Incannex Healthcare Limited Sponsored ADR ( (IXHL) ) has shared an announcement.
On February 24, 2026, Incannex Healthcare filed a certificate of amendment in Delaware to implement a 1-for-30 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on February 26, 2026, with post-split trading on the Nasdaq Capital Market to commence on February 27, 2026 under the existing ticker IXHL and a new CUSIP. The board-approved split, previously authorized by shareholders in May 2025, will shrink the share count from about 358.3 million to roughly 11.9 million without changing authorized capital, and is aimed at boosting the stock’s per-share trading price to help the company regain compliance with Nasdaq’s minimum bid price requirement, while rounding up any fractional positions to whole shares for investors.
The 1-for-30 consolidation will automatically adjust outstanding equity awards, option exercise prices and plan share pools on a proportional basis, leaving the economic interest of investors unchanged aside from the higher nominal share price. Operationally, the move signals management’s focus on preserving the Nasdaq listing, a key platform for liquidity and future capital raising, with most shareholders seeing their positions adjusted electronically and only holders of physical certificates required to follow transfer-agent instructions for exchanging into post-split stock.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
Spark’s Take on IXHL Stock
According to Spark, TipRanks’ AI Analyst, IXHL is a Neutral.
The score is held down primarily by weak financial performance (large losses and negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Offsetting these are positive corporate developments (Fast Track designation and positive clinical progress) and a low-leverage balance sheet, while valuation is difficult to assess due to loss-making results and no dividend data.
To see Spark’s full report on IXHL stock, click here.
More about Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Inc. is a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. Its lead programs, such as IHL-42X, IHL-675A and PSX-001, target disorders with limited or inadequate approved treatment options, positioning the company in niche, underserved therapeutic markets.
Average Trading Volume: 13,407,380
Technical Sentiment Signal: Sell
Current Market Cap: $98.18M
Find detailed analytics on IXHL stock on TipRanks’ Stock Analysis page.